Velpatasvir clinical trials
Also written GS-5816.
Counted the way a researcher would: Velpatasvir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses velpatasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the velpatasvir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Jun 2016 · EPCLUSA · NDA 208341 (FDA, Drugs@FDA; in a combination)
- European Union
- 6 Jul 2016 · Epclusa · EMEA/H/C/004210 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
55 studies that test it; most in 2015 (9)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 9 |
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 31 · Other 24
Gilead Sciences (31) · Kirby Institute (3) · Catherine Anne Chappell (1) · Amit D Tevar, MD (1) · Mary E. Keebler, MD (1) · Fernanda P Silveira, MD, MS (1) · Elizabeth Krans, MD (1) · Alexandria University (1)
Often tested with
Tested in the same studies.
Sofosbuvir (30) · Voxilaprevir (10) · Ribavirin (7) · Sofosbuvir velpatasvir voxilaprevir drug combination (2) · Ledipasvir, sofosbuvir drug combination (2) · Ledipasvir (1) · Glecaprevir and pibrentasvir (1) · Interferons (1)
Studies
Open first, then newest update. How each study uses velpatasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 55
- Hepatitis C Treatment in Idaho County JailsNot yet recruitingNot applicableEastern Idaho Public HealthNCT06533319Written as sofosbuvir/velpatasvirHow we know
- Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During PregnancyActive, not recruitingPhase 4Catherine Anne ChappellNCT05140941Written as Sofosbuvir/Velpatasvir 400 MG-100 MG Oral TabletHow we know
- Expanding the Pool in Orthotopic Heart TransplantationCompletedPhase 2Mary E. Keebler, MDNCT03222531Written as sofosbuvir/velpatasvirHow we know
- The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant RecipientsCompletedPhase 2Fernanda P Silveira, MD, MSNCT03819322Written as sofosbuvir/velpatasvirHow we know
- The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant RecipientsActive, not recruitingPhase 2Amit D Tevar, MDNCT03809533Written as sofosbuvir/velpatasvirHow we know
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedPhase 4M.D. Anderson Cancer CenterNCT05717400Written as VelpatasvirHow we know
- Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)Status unknownPhase 4Macfarlane Burnet Institute for Medical Research and Public Health LtdNCT05016609Written as Sofosbuvir/Velpatasvir (Gilead)How we know
- Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C InfectionCompletedPhase 4Elizabeth Krans, MDNCT03057847Written as Sofosbuvir/VelpatasvirHow we know
- HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled TrialCompletedPhase 4Alexandria UniversityNCT04653818Written as Velpatasvir/SofosbuvirHow we know
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedPhase 2Fondazione Italiana Linfomi - ETSNCT02836925Written as Sofosbuvir+VelpatasvirHow we know
- A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsCompletedNot applicableKirby InstituteNCT03492112Written as Sofosbuvir/velpatasvirHow we know
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated CirrhosisStatus unknownPhase 4Peking University People's HospitalNCT05467826Written as Sofosbuvir/Velpatasvir + RibavirinHow we know
- Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated CirrhosisCompletedPhase 3Gilead SciencesNCT04112303Written as SOF/VELHow we know
- Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA ExperienceCompletedPhase 2University of Maryland, BaltimoreNCT02745535Written as Sofosbuvir/Velpatasvir/VoxilaprevirHow we know
- Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active InfectionCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT03512210Written as Sofosbuvir/Velpatasvir (SOF/VEL)How we know
- Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) InfectionCompletedPhase 3Gilead SciencesNCT04211909Written as SOF/VELHow we know
- Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in BrazilStatus unknownNot applicableHospital de Clinicas de Porto AlegreNCT04039698Written as Velpatasvir/SofosbuvirHow we know
- The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in ChinaStatus unknownPhase 4Peking University First HospitalNCT04997564Written as Sofosbuvir / VelpatasvirHow we know
- Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/VelpatasvirCompletedPhase 2Hannover Medical SchoolNCT03818308Written as Sofosbuvir and VelpatasvirHow we know
- A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction ClinicCompletedPhase 4Community Research Initiative of New EnglandNCT03235154Written as sofosbuvir/velpatasvirHow we know
See all 55 studies that test velpatasvir →
Given beside what is tested · 9 — velpatasvir is usual care or a partner of the new treatment
- Combating Related Epidemics in HCVNot yet recruitingPhase 4Duke UniversityNCT07560046Written as Sofosbuvir/Velpatasvir/VoxilaprevirHow we know
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and TanzaniaRecruitingEarly Phase 1Médecins du MondeNCT06159504Written as sofosbuvir/velpatasvir (SOF/VEL)How we know
- Transplanting Hepatitis C Positive OrgansStatus unknownPhase 4Brigham and Women's HospitalNCT03086044Written as Sofosbuvir/velpatasvirHow we know
- deLIVER: Direct Acting Antiviral Effects on the LiverCompletedPhase 4Johns Hopkins UniversityNCT02938013Written as Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]How we know
- Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)CompletedPhase 2Cocrystal Pharma, Inc.NCT03501550Written as SOF/VELHow we know
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 1Gilead SciencesNCT02185794Written as SOF/VELHow we know
- Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisCompletedPhase 3Gilead SciencesNCT02996682Written as SOF/VELHow we know
- Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and CirrhosisCompletedPhase 2Gilead SciencesNCT02781558Written as SOF/VELHow we know
- Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected PatientsCompletedPhase 4National Taiwan University HospitalNCT03250910Written as Sofosbuvir and VelpatasvirHow we know
As the comparator · 2 — what is tested is compared with velpatasvir
- deLIVER: Direct Acting Antiviral Effects on the LiverCompletedPhase 4Johns Hopkins UniversityNCT02938013Written as Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]How we know
- Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole TabletWithdrawnPhase 4Radboud University Medical CenterNCT03389061Written as sofosbuvir/velpatasvir tabletHow we know
Codes
What other systems call velpatasvir · ClinicalTrials.gg INT000378
- MeSH (NLM) C000604171velpatasvirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KCU0C7RS7ZVELPATASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1799206Confirmed FDA, Wikidata
- Wikidata Q25018296velpatasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152851VelpatasvirOne source FDA
- DrugBank DB11613One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604171 | velpatasvir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KCU0C7RS7Z | VELPATASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1799206 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25018296 | velpatasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152851 | Velpatasvir | One source FDA |
| DrugBank | DB11613 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.